Interactive Tool for Managing BTK Inhibitor−Associated AEs in Hematologic Malignancies: A Global Perspective

[lankisterguy]

The following is intended for medical professionals and uses moderate Med-Speak - you may need to register and download the app to use it as intended. -Len

++++++++++++++++++++++++++++

Interactive Tool for Managing BTK Inhibitor−Associated AEs in Hematologic Malignancies: A Global Perspective

Florence Cymbalista, MD, PhD | Toby Eyre, MBChB, MD | Aron Kater, MD, PhD | Stephan Stilgenbauer, MD | Alessandra Tedeschi, MD

Access this free Interactive Decision Support Tool to compare your choice of therapy for patients with adverse events associated with BTK inhibitors with those of 5 renowned experts from the United Kingdom, France, Italy, Germany, and the Netherlands based on specific patient characteristics that YOU enter. On average, after seeing the treatment recommendations, your colleagues change their treatment plan in 40% of cases entered.

Access the Tool

clinicaloptions.com/CE-CME/...?

Don’t have the CCO Interactive Decision Support Tool app?

Get access to all CCO Interactive Decision Support Tools by downloading from your specific app store.

An installment in the educational program:

Global Perspectives and Clinical Resources on BTK Inhibitor Therapy for Patients With CLL

++++++++++++++++++++++

clinicaloptions.com/CE-CME/...

Introduction

Use this Interactive Decision Support Tool to learn strategies to assess and manage adverse events associated with BTK inhibitors from 5 international experts in managing patients with hematologic malignancies.

Interactive Decision Support Tool

What hematologic malignancy does your patient have?

Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)

Mantle cell lymphoma (MCL)

Marginal zone lymphoma (MZL)

Waldenström macroglobulinemia (WM)

Has your patient already begun treatment with a BTK inhibitor?

No, but BTK inhibitor therapy is planned

Yes

Interactive Decision Support Tool

What hematologic malignancy does your patient have? Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) [Change]

Has your patient already begun treatment with a BTK inhibitor? Yes [Change]

Is your patient experiencing an adverse event (AE) or planning a medical procedure?

Experiencing AE

Planning an invasive medical procedure

[neurodervish]

Thanks for sharing this Len. It's very helpful.